Legend Biotech

Our Global Head of Talent Development, Laurence Andrianne, is in London this week to host a roundtable discussion at Leap HR Life Sciences Europe! Join her for “Enhancing Employee Engagement to Increase Retention,” a thought-provoking discussion that is part of the Speed Learning session on Friday, February 20, at 2 p.m. GMT. Find out more: https://lnkd.in/eH6FmUkT #LeapHR #HumanResoruces

Recently, Legend’s Senior Vice President of Global Manufacturing and Supply, Birk Vanderweeën, discussed his unique insights with Jon O'Connell at Cell & Gene about our approach to adopting new technologies and ensuring continuous improvement in our commercial bioprocessing operations. Read more here: https://lnkd.in/ehTmrPEw #CART #CellTherapy

As the demand for our #CellTherapy increases, it is crucial to have a robust onboarding and training framework that ensures new employees thrive in a highly regulated environment.   In just three years, we have welcomed 700+ professionals across our two state-of-the-art manufacturing sites in Ghent to expand capacity and meet patients’ needs.   Voka Oost-Vlaanderen invited our Associate Director Head of Training & Capabilities, Sofie Vercruysse, and Senior Director of HR Europe, An Moernaut, to discuss how structured training and a people-centric approach ensure operational excellence.   Read more: https://lnkd.in/e-f8w9Cm   #WeAreLegend #BiotechManufacturing #BiotechCareers #CellTherapy #CART

The Legend Biotech team is attending the #Tandem25 Meetings of ASTCT (The American Society for Transplantation and Cellular Therapy) and CIBMTR (Center for International Blood & Marrow Transplant Research) this week. If you are on-site, visit our booth at 513! We're excited to learn, network, and discuss new data on our CAR T #CellTherapy for #MultipleMyeloma. #CART

On the eve of #InternationalDayofWomenandGirlsinScience, we honor the brilliant women and girls shaping the future of science and medicine, especially in #oncology. Your contributions drive innovation and inspire groundbreaking therapies for patients worldwide. To every young girl aspiring for a future in STEM: Your curiosity, creativity, and courage are vital to building a healthier, brighter world. We support you and are committed to breaking down the barriers to women's participation in STEM fields. #February11 #WomenInScience

On #WorldCancerDay, we join the global community in recognizing the strength and resilience of those affected by cancer. At Legend Biotech, we are committed to developing innovative cell therapies that address the unmet needs of cancer patients. We believe everyone deserves access to the best possible care, regardless of their diagnosis, and that people are at the center of care. We are #UnitedbyUnique.

What a fantastic New Year's celebration with the incredible team in Ghent! We toasted a year of achievements in #CellTherapy and expressed our gratitude for the dedication and hard work of our LEGENDary colleagues. We are excited to carry this momentum into the new year and continue to make a difference in the lives of #MulitpleMyeloma patients. #CompanyCulture #WeAreLegend

Our Senior Director of CAR-T Operations, Sarah Snykers, PhD, and Head of Manufacturing Sciences & Technology (MS&T), Pieter Jacobs, are in Dallas this week attending Phacilitate’s #AdvancedTherapiesWeek! Be sure to catch Sarah’s presentation, “CAR-T EU Manufacturing Footprint: From Start-Up to Commercial Ramp-Up,” scheduled for tomorrow, Tuesday, January 21, at 12:15 p.m., where she will share insights from our rapid expansion of cutting-edge CAR-T production in Ghent, Belgium, highlighting key learnings from this real-world experience. Learn more: https://lnkd.in/gk9V_Dsw #ATW25 #AdvancedTherapies #CellTherapy

#ICYMI: Join our CEO, Ying Huang, as he shares Legend Biotech’s latest updates during the J.P. Morgan Healthcare Conference tomorrow, January 14, 2025, at 3:45 p.m. PT.   Learn more and register to access the live audio webcast: https://bit.ly/LEGNJPM #JPMorganHealthcare #CellTherapy #JPM25

At Legend Biotech, we are laser-focused on transforming the future of cancer treatment. From our state-of-the-art Obelisc facility in Ghent, Belgium — the largest CAR-T production site in Europe with more than 630 dedicated employees — we are developing personalized therapies that offer hope and a new chance at life to #MutlitpleMyeloma patients across Europe. Check out this interview with De Tijd, featuring Yannick Werniers and Frederik Buysse, who offer an in-depth overview of our manufacturing process. Read more: https://lnkd.in/eCVd-4AP #CellTherapy #CART #Innovation #WeAreLegend